


A new Medication From Zeta Pharma To Fight Resistant Bacteria

CAIRO, EGYPT, November 30, 2021 /EINPresswire.com/ -- In a continuation of its commitment to provide the Egyptian community with distinctive medications, Zeta pharma recently launched its new product; Cubizolid, an antibiotic that belongs to a new class of antibacterials.

This product launch comes after the introduction of other special products from zeta pharma; Bilastegic, Medihyalo, and Empacoza.

Cubizolid contains tedizolid phosphate, which was approved by the FDA on June 20, 2014, for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Despite the continuous global medical efforts to combat the spread of microbial resistance, multidrugresistant organisms, including grampositive bacteria such as methicillinresistant Staphylococcus aureus (MRSA), remain a massive public health threat.



MRSA can cause mild to life-threatening diseases and is related to thousands of worldwide deaths every year. Therefore, Zeta pharma decided to provide the Egyptian healthcare professionals with a high-quality medicinal solution for this dilemma.

Cubizolid belongs to the Oxazolidinones group of antibiotics which is effective against multidrugresistant bacteria and capable of overcoming resistance through inhibiting bacterial protein synthesis. Tedizolid is proven by the clinical studies to be more effective and more tolerable than linezolid, the previously approved member of the same class.

Zeta pharma introduced Cubizolid to the Egyptian market in a pack of 6 tablets of 200 mg of tedizolid phosphate to be administered in a once-daily dose for the convenience of the patient.

In El-Sadat city, Zeta pharma designed a state-of-art production facility that is referenced by CGMP, WHO guidelines, and international standards, with the latest high tech production equipment and high standard quality systems, to produce solid dosage form medications with a planned extension to produce high potent drugs such as immunosuppressants and oral anti-cancer drugs.

Zeta Pharma, an Egyptian company, aims to alleviate the financial burden of the society by providing locally manufactured high-quality products. Since its start in 2015, Zeta Pharma continued to offer essential medicines to the Egyptian patient, with a future portfolio of more than 150 medications in different therapeutic classes.

Dr. Faris Salama Zeta pharma +2 0102 222 8221 email us here Visit us on social media: Facebook LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/557313772

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.